About Us
GeneLeap Biotech is a global company in the Luye Life sciences portfolio of companies,a leader in China and a new entrant in the US. Our goal is to deliver a best-in-class portfolio of completely novel RNA&mRNA based drugs and vaccines.
Leveraging recent breakthroughs in mRNA therapy
GeneLeap Biotech leverages recent breakthroughs in nucleic acid technologies to deliver solutions for infectious diseases and cancer. Targeting patient populations with urgent and unmet medical needs, we innovate in the precision medicine space to bring about positive impact to difficult prognoses.
Executive Team
- Deeply engaged in the research and industrialization of antitumor drugs and lipid nano particle preparations for more than 30+ years.
- More than 20 new drugs or preparations have been developed.
- Paclitaxel Liposome for Injection invented by him is the only product on the market at present.
- PhD in Polymer Science from University of Akron and Postdoc training in Princeton Universtiy.
- More than 15 years of experience on drug delivery system development in pharmaceutical industry. Before joining Geneleap, he served as Vice President in Luye Pharma and led the novel drug delivery technologies department and Luye’s Beijing R&D center.
- More than 20 years experience in scientific research management of pharmaceutical enterprises.
- Expert of liposomal drug development and industrialization.
- PhD from Genoa University and Postdoctoral training from Yale Medical School
- Throughout her tenures at the Wyss Institute, Moderna, JnJ and other small companies she has specialized in different drug modalities, built large departments and delivered on portfolio expansion and clinical-stage programs.
- PhD from University of Delhi, India and postdoctoral training from Massey University, New Zealand, and Harvard Medical School. Previously, Associate Director, Immunology at Spring Bank Pharmaceuticals.
- More than 20 years of experience in drug development industry with expertise in small molecules and nucleic acid therapeutics, including innate immune receptor agonists and antagonists, antisense and siRNA.
- Co-inventor of 33 US patents and co-author of 50+ peer-reviewed publications.
- Over 15 years of industrial experience in gene/drug delivery and has been involved in IND, phase I-III clinical supplies, and NDA in China, EU and USA.
- Previous head of formulation at HUTCHMED, China, scientist at TransMIT, Germany and senior investigator at Luye Pharma, USA.
- Holds a series of issued gene/drug delivery patents and published 30+ gene/drug delivery papers. BEng and PhD from Jilin University, China.
Board of Advisors
Dr. Langer’s pioneering work in the study and development of polymers to deliver drugs, particularly macromolecules, has lead to countless breakthroughs in the filed of biotechnology, and has led to the advancement of countless therapeutics.
Dr. Langer will advise on the development of delivery platforms for non-messenger RNA therapeutic approaches.
Dr. D. Weissman is a Professor in the Department of Medicine and Director of Vaccine Research in the Infectious Diseases Division at the Perelman School of Medicine at the University of Pennsylvania. Dr. D. Weissman and his collaborator, Dr. KatalinKarikó discovered a therapeutic technology based on the modification of mRNA.
His work helped enable development of effective mRNA vaccines, the best known of which are those for COVID-19 produced by BioNTech/Pfizer and Moderna. Upon this, he received Lasker-DeBakey Clinical Medical Research Award.
Partners
- MIT
- Peking University
